Effect of curcumin supplementation in patients with lupus

Effect of curcumin supplementation on disease activity, inflammatory factors and oxidative stress in patients with Systemic Lupus Erythematosus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210425051077N1

Enrollment

Registered

2021-09-12

Start date

2021-07-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus. Systemic lupus erythematosus (SLE)

Interventions

Intervention 1: Intervention group: curcumin group will receive two 500 mg curcumin capsules (Karen Co.) daily for 10 weeks. Intervention 2: Control group: control group will receive two placebo capsu

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Not using any nutritional supplements within 2 months before the beginning of the study except calcium-vitamin D supplement No history of gallstones Not following a special diet Not using anticoagulant drugs Not having Coronavirus Disease Age between 18 and 60 years old

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Change in type and dose of drugs Following a special diet during the study Starting to take any dietary supplements during the study Having Coronavirus Disease

Design outcomes

Primary

Measure	Time frame
High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Westergren method.;C3 complement. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;C4 complement. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Total Complement. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Anti double stranded DNA antibody. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Interleukin-6. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Protein carbonyl. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Disease activity. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Systemic Lupus Erythematosus Disease Activity Index 2000 Questionnaire.;Nitric oxide. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;8-isoprostane. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Matrix metalloproteinase 9. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.	—

Measure

Time frame

High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Westergren method.;C3 complement. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;C4 complement. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Total Complement. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Anti double stranded DNA antibody. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Interleukin-6. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;Protein carbonyl. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Disease activity. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Systemic Lupus Erythematosus Disease Activity Index 2000 Questionnaire.;Nitric oxide. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: Standard kit.;8-isoprostane. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.;Matrix metalloproteinase 9. Timepoint: At the beginning of the study and after 10 weeks intervention. Method of measurement: ELISA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElahe Mohammadi

Khalkhal University of Medical Sciences

E.mohamadi52@yahoo.com+98 45 3243 2002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026